Carregant...
Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
Monoclonal antibodies directed against interleukin (IL)‐5, such as mepolizumab and benralizumab, are an effective and established treatment for severe eosinophilic asthma. Here, we present a patient with eosinophilic asthma with a partial clinical response to mepolizumab initially, as measured by th...
Guardat en:
| Publicat a: | Respirol Case Rep |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Ltd
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8013786/ https://ncbi.nlm.nih.gov/pubmed/33815803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.742 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|